Pfizer und BioNTech veröffentlichen erste positive Daten aus laufender Phase-1/2-Studie mit mRNA-basiertem SARS-CoV-2-Impfstoffkandidaten
01 juil. 2020 09h01 HE
|
BioNTech SE
In der laufenden verblindeten, Placebo-kontrollierten Phase-1/2-Studie in den USA wird ein nukleosidmodifizierter messenger-RNA-Impfstoffkandidat (BNT162b1), der für die Rezeptorbindungsdomäne (RBD)...
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
01 juil. 2020 09h01 HE
|
BioNTech SE
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD)...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
23 juin 2020 07h00 HE
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
23 juin 2020 00h59 HE
|
Translate Bio, Inc.
-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases -- -- Translate Bio to receive...
Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
17 juin 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
16 juin 2020 08h19 HE
|
Biomerica, Inc.
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced...
Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test
12 juin 2020 08h00 HE
|
Cue Health Inc.
SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today that it has received Emergency Use Authorization (“EUA”) from the U.S. Food and...
Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic
11 juin 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform
10 juin 2020 09h00 HE
|
Cue Health Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today the close of its Series C financing round, raising $100 million in new capital....
Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
08 juin 2020 08h00 HE
|
BioLargo, Inc.
AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental...